Nishadil
Signup Signin
Delhi | 25°C (windy)
The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal

The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal
The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition

The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition
The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic

The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic
Pfizer's Colossal $4.9 Billion Bet: A Game-Changer in the Obesity Treatment Arena

Pfizer's Colossal $4.9 Billion Bet: A Game-Changer in the Obesity Treatment Arena
A New Dawn in Oncology: Kite Pharma's $350 Million Acquisition of Interius Biotherapeutics Set to Revolutionize CAR T-Cell Therapy

A New Dawn in Oncology: Kite Pharma's $350 Million Acquisition of Interius Biotherapeutics Set to Revolutionize CAR T-Cell Therapy
Load more..